文献速递帕金森病与运动障碍

ADS-5102(金刚烷胺)缓释胶囊治疗帕金森病左旋多巴诱导的运动障碍:EASE LID随机临床试验

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2017-01-01

这项随机双盲安慰剂对照试验纳入121例每日至少1小时令人困扰的运动障碍的帕金森病患者,评估睡前口服ADS-5102 274mg的疗效与安全性。第12周时,ADS-5102组统一运动障碍评定量表总分较基线降低15.9分,安慰剂组降低8.0分,组间差异-7.9分(95%CI -12.5至-3.3,P<.001),且OFF时间减少0.9小时(95%CI -1.6至-0.2,P=.02)。常见不良事件包括视幻觉、外周水肿和头晕。

要点

  • ADS-5102 274mg睡前口服可显著改善帕金森病患者的运动障碍,第12周统一运动障碍评定量表总分较安慰剂多降低7.9分。
  • ADS-5102还使OFF时间较安慰剂减少0.9小时(95%CI -1.6至-0.2,P=.02)。
  • 常见不良事件为视幻觉(23.8% vs 1.7%)、外周水肿(23.8% vs 0)和头晕(22.2% vs 0),20.6%的患者因不良事件停药。

核心结论

  • ADS-5102 274mg睡前口服可能有效治疗帕金森病左旋多巴诱导的运动障碍,并额外减少OFF时间。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,2014年5月7日至2015年7月22日在44个北美站点开展。
  • 筛查189例,随机126例,改良意向治疗人群121例(女性51例,男性70例;平均年龄64.7岁,SD 9.1)。
  • 患者随机接受安慰剂或ADS-5102 274mg睡前口服,最长25周。

主要发现

  • 第12周统一运动障碍评定量表总分最小二乘均值(SE)变化:ADS-5102组-15.9(1.6),安慰剂组-8.0(1.6),治疗差异-7.9(95%CI -12.5至-3.3,P<.001)。
  • OFF时间平均(SE)变化:ADS-5102组减少0.6(0.3)小时,安慰剂组增加0.3(0.3)小时,治疗差异-0.9小时(95%CI -1.6至-0.2,P=.02)。
  • 常见不良事件(ADS-5102 vs 安慰剂):视幻觉15例(23.8%)vs 1例(1.7%),外周水肿15例(23.8%)vs 0例,头晕14例(22.2%)vs 0例。
  • 因不良事件停药:ADS-5102组13例(20.6%),安慰剂组4例(6.9%)。

关键数值与推荐

  • 主要疗效终点为第12周统一运动障碍评定量表总分较基线的变化。
  • 关键次要终点为OFF时间。

临床怎么用

  • 对于每日至少1小时令人困扰的运动障碍且至少轻度功能影响的帕金森病患者,可考虑睡前口服ADS-5102 274mg。
  • 用药期间需监测视幻觉、外周水肿和头晕等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need. OBJECTIVE: To evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release 274-mg capsules for treatment of LID in patients with PD. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled clinical trial was conducted between May 7, 2014, and July 22, 2015, at 44 North American sites among patients with PD treated with levodopa who experienced at least 1 hour of troublesome dyskinesia per day with at least mild functional impact. INTERVENTIONS: Patients were randomized to receive placebo or 274 mg of ADS-5102 administered orally at bedtime for up to 25 weeks. MAIN OUTCOMES AND MEASURES: The primary efficacy analysis was the change from baseline to week 12 in the Unified Dyskinesia Rating Scale total score for ADS-5102 vs placebo in the modified intent-to-treat population. OFF time (amount of time the PD medication is not controlling motor symptoms) was a key secondary end point. Safety analyses included all patients who received the study drug (ADS-5102 or placebo). RESULTS: A total of 189 patients were screened, and 126 were randomized; the modified intent-to-treat population included 121 patients (51 women and 70 men; mean [SD] age, 64.7 [9.1] years). At week 12, the least-squares mean (SE) change in the Unified Dyskinesia Rating Scale score was -15.9 (1.6) for ADS-5102 (n = 63) and -8.0 (1.6) for placebo (n = 58) (treatment difference, -7.9; 95% CI, -12.5 to -3.3; P < .001). OFF time decreased by a mean (SE) of 0.6 (0.3) hours for ADS-5102 and increased by 0.3 (0.3) hours for placebo (treatment difference, -0.9 hours; 95% CI, -1.6 to -0.2; P = .02). Common adverse events for ADS-5102 vs placebo included visual hallucinations (15 [23.8%] vs 1 [1.7%]), peripheral edema (15 [23.8%] vs 0), and dizziness (14 [22.2%] vs 0). Adverse events led to treatment discontinuation for 13 patients receiving ADS-5102 (20.6%) vs 4 patients receiving placebo (6.9%). CONCLUSIONS AND RELEVANCE: ADS-5102, 274 mg at bedtime, may be an effective treatment for LID. An additional benefit is reduced OFF time. To our knowledge, this is the first demonstration of an oral treatment reducing both LID and OFF time in patients with PD with dyskinesia. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02136914.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol. 2017. PMID: 28604926. doi:10.1001/jamaneurol.2017.0943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。